Latest media releases


UBS hosts Global Pharmaceuticals Conference

| Media Releases Americas

NEW YORK, May 23, 2005 - The UBS Global Pharmaceuticals Conference begins today at the Grand Hyatt in New York City and runs through tomorrow, May 24. More than 1,400 portfolio managers, analysts, and investors are scheduled to attend. The conference features presentations by senior executives from a comprehensive group of drug delivery, generic and other pharmaceutical companies representing over 90 pharmaceutical firms from 14 different countries.

Pharmaceuticals continues to be one of the most rapidly growing sectors in healthcare and 2005 will undoubtedly be another promising year within this sector as new drug approvals and launches spur growth and we see continued differentiation within the sector.


Acambis plc
Advancis Pharmaceutical Corp.
Alimera Sciences
Alkermes, Inc.
Anadys Pharmaceuticals, Inc.
Andrx Corporation
Angiotech Pharmaceuticals, Inc.
Antares Pharma, Inc.
Auxilium Pharmaceuticals, Inc.
Axcan Pharma Inc.
Barr Pharmaceuticals, Inc.
Barrier Therapeutics, Inc.
Berna Biotech AG
betapharm Arzneimittel GmbH
Bioenvision, Inc.
BioSante Pharmaceuticals, Inc.
Biovail Corporation
Bradley Pharmaceuticals, Inc.
CardioKine, Inc.
Cardiome Pharma Corp.
Celgene Corporation
Columbia Laboratories, Inc.
ConjuChem Inc.
Curis, Inc.
Cypress Bioscience, Inc.
CytRx Corporation
EGIS Pharmaceuticals Ltd.
Encysive Pharmaceuticals Inc.
Endo Pharmaceuticals Holdings
EPIX Pharmaceuticals, Inc.
Eyetech Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
First Horizon Pharmaceutical
Flamel Technologies S.A.
Genaera Corporation
Geron Corporation
Glenmark Pharmaceuticals Ltd.
Hi-Tech Pharmacal Co., Inc.
Icagen, Inc.
Inamed Corporation
Inhibitex, Inc.
InKine Pharmaceutical Company, Inc.
Insmed, Inc.
Isis Pharmaceuticals, Inc.
Isolagen, Inc.
ISTA Pharmaceuticals, Inc.
IVAX Corporation
Jubilant Organosys, Ltd.
King Pharmaceuticals, Inc.
K-V Pharmaceutical Co.
Labopharm Inc.
Lupin Limited
Matrixx Initiatives, Inc.
The Medicines Company
Medicis Pharmaceutical Corp.
MGI Pharma, Inc.
Nabi Biopharmaceuticals
Nastech Pharmaceutical
Nektar Therapeutics
NeoPharm, Inc.
Neose Technologies, Inc.
Neurochem Inc.
New River Pharmaceuticals Inc.
Northfield Laboratories Inc.
Novavax, Inc.
Novozymes A/S
Pain Therapeutics, Inc.
Paladin Labs Inc.
Palatin Technologies, Inc.
Pharmion Corporation
PLIVA d.d
Pozen, Inc.
Progenics Pharmaceuticals, Inc.
Prometheus Laboratories Inc.
QLT Inc.
Ranbaxy Laboratories Limited
Recordati S.p.A.
Rigel Pharmaceuticals, Inc.
Salix Pharmaceuticals, Ltd.
Santarus, Inc.
Savient Pharmaceuticals, Inc.
SciClone Pharmaceuticals, Inc.
ScinoPharm Taiwan, Ltd.
Sepracor Inc.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SkyePharma PLC
Somaxon Pharmaceuticals, Inc.
SuperGen, Inc.
Taro Pharmaceutical Industries
Telik, Inc.
UCB S.A.
Vela Pharmaceuticals Inc.
ViaCell, Inc.
VIVUS, Inc.
Zeneus Pharma


Online conference information To access audio transmissions and the conference agenda please go to the UBS Investment Bank website at www.ibb.ubs.com. Audio transmissions of company presentations will be available live and by replay. Replays will begin three hours after the actual presentation time and will be available on the site for four weeks.

UBS Investment Bank is a business group of UBS AG (NYSE: UBS), one of the world's leading financial firms. The investment banking and securities business is among the select bracket of major global houses, providing a full range of products to institutional and corporate clients, intermediaries, governments and hedge funds. UBS employs around 68,000 people in 50 countries and is listed on the New York, Tokyo and Zurich stock exchanges.


Inquiries: Allison Chin-Leong +1-212-882-5693 (office)